Obviously nine believers: Actionable germline genetic variants for pre‐emptive pharmacogenetic testing

A recent publication in Clinical Pharmacology and Therapeutics (CPT) by van der Wouden and colleagues on the pre-emptive pharmacogenomic PGx Passport, intended to optimize drug prescribing, caught my attention.1 I believe that the overall narrative of the paper is disproportional to the supporting evidence. The editors of CPT did not find that my comment and reflections on this paper could be prioritized. I hope that BCPT will endorse a...